{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:42:23Z","timestamp":1776087743366,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.braindev.2004.01.005","type":"journal-article","created":{"date-parts":[[2004,4,10]],"date-time":"2004-04-10T09:39:29Z","timestamp":1081589969000},"page":"497-505","source":"Crossref","is-referenced-by-count":25,"title":["Recent advances in the biochemistry and genetics of sphingolipidoses"],"prefix":"10.1016","volume":"26","author":[{"given":"Hatice Asuman","family":"\u00d6zkara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2004.01.005_BIB1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1073\/pnas.012540899","article-title":"Inaugural article: the glycosynapse","volume":"99","author":"Hakamori","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2004.01.005_BIB2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1098\/rstb.2003.1274","article-title":"Formation of functional cell membrane domains: the interplay of lipid- and protein-mediated interactions","volume":"358","author":"Harder","year":"2003","journal-title":"Philos Trans R Soc Lond B"},{"key":"10.1016\/j.braindev.2004.01.005_BIB3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1146\/annurev.bi.50.070181.003505","article-title":"Glycosphingolipids in cellular interactions, differentiation and oncogenesis","volume":"50","author":"Hakamori","year":"1981","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"10.1016\/j.braindev.2004.01.005_BIB4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.braindev.2004.01.005_BIB5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/0962-8924(96)80999-8","article-title":"Topology of glycosphingolipid degradation","volume":"6","author":"Sandhoff","year":"1996","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.braindev.2004.01.005_BIB6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0005-2760(92)90210-M","article-title":"Activator proteins and topology of lysosomal sphingolipid catabolism","volume":"1126","author":"F\u00fcrst","year":"1992","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.braindev.2004.01.005_BIB7","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1515\/bchm2.1964.339.1.260","article-title":"Eine cerebrosidsulfatase aus schweineniere","volume":"339","author":"Mehl","year":"1964","journal-title":"Hoppe-Seyler's Z Physiol Chem"},{"key":"10.1016\/j.braindev.2004.01.005_BIB8","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1515\/bchm2.1979.360.2.1837","article-title":"Purification and characterization of an activator protein for the degradation of glycolipids GM2 and GA2 by hexosaminidase A","volume":"360","author":"Conzelmann","year":"1979","journal-title":"Hoppe-Seyler's Z Physiol Chem"},{"key":"10.1016\/j.braindev.2004.01.005_BIB9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1515\/bchm3.1988.369.1.317","article-title":"The precursor of sulfatide activator protein is processed to three different proteins","volume":"369","author":"F\u00fcrst","year":"1988","journal-title":"Biol Chem Hoppe Seyler"},{"key":"10.1016\/j.braindev.2004.01.005_BIB10","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1073\/pnas.86.9.3389","article-title":"Saposin A: second cerebrosidase activator protein","volume":"86","author":"Morimoto","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2004.01.005_BIB11","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1515\/bchm3.1987.368.2.1571","article-title":"Complete aminoacid sequence and carbohydrate content of the naturally occuring glucosylceramide activator protein (A1 activator) absent from a new human Gaucher disease variant","volume":"368","author":"Kleinschmidt","year":"1987","journal-title":"Biol Chem Hoppe Seyler"},{"key":"10.1016\/j.braindev.2004.01.005_BIB12","series-title":"The metabolic and molecular basis of inherited disease","first-page":"3371","article-title":"Sphingolipid activator proteins","author":"Sandhoff","year":"2001"},{"issue":"10","key":"10.1016\/j.braindev.2004.01.005_BIB13","first-page":"455","article-title":"Enzymology of lysosomal glycolipid catabolism","volume":"56","author":"Kolter","year":"1988","journal-title":"Trends Glycosci Glycotechnol"},{"key":"10.1016\/j.braindev.2004.01.005_BIB14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/32440","article-title":"A lipid associated with the antiphospholipid syndrome regulates endosome structure and function","volume":"392","author":"Kobayashi","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.braindev.2004.01.005_BIB15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF00219682","volume":"92","author":"Bradova","year":"1993","journal-title":"Hum Genet"},{"key":"10.1016\/j.braindev.2004.01.005_BIB16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0014-5793(92)81529-U","article-title":"Uptake and metabolism of fluorescent ceramide analogs by rat oligodendrocytes in culture","volume":"314","author":"Giudici","year":"1992","journal-title":"Fed Eur Biochem Soc Lett"},{"key":"10.1016\/j.braindev.2004.01.005_BIB17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/glycob\/6.1.33","article-title":"Pathway of glycosphingolipid biosynthesis in SW13 cells in the presence and absence of vimentine intermediate filaments","volume":"6","author":"Gillard","year":"1996","journal-title":"Glycobiology"},{"key":"10.1016\/j.braindev.2004.01.005_BIB18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1023\/A:1005454602454","article-title":"Sphingolipids and cell signaling","volume":"21","author":"Fredman","year":"1998","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.braindev.2004.01.005_BIB19","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.1021\/bi00076a009","article-title":"Glycosphingolipid-enriched, detergent-insoluble complexes in protein sorting in epithelial cells","volume":"32","author":"Fiedler","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.braindev.2004.01.005_BIB20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/jnr.490420316","article-title":"Cloning and characterization of MVP17: a developmentally regulated myelin protein in oligodendrocytes","volume":"42","author":"Kim","year":"1995","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.braindev.2004.01.005_BIB21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF00971340","article-title":"Maintenance of membrane sheets by cultured oligodendrocytes requires continuous microtubule turnover and Golgi transport","volume":"19","author":"Benjamins","year":"1994","journal-title":"Neurochem Res"},{"issue":"4","key":"10.1016\/j.braindev.2004.01.005_BIB22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1042\/bst0270432","article-title":"Regulation of sphingolipid and glycosphingolipid metabolism during neuronal growth and development","volume":"27","author":"Futerman","year":"1999","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.braindev.2004.01.005_BIB23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-2275(20)39839-4","article-title":"Krabbe disease: a galactosylsphingosine (psychosine) lipidoses","volume":"21","author":"Svennerholm","year":"1980","journal-title":"J Lipid Res"},{"key":"10.1016\/j.braindev.2004.01.005_BIB24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0005-2760(82)90272-7","article-title":"The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher's disease","volume":"712","author":"Nilsson","year":"1982","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.braindev.2004.01.005_BIB25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1126\/science.6719111","article-title":"Progressive accumulation of toxic metabolite in a genetic leukodystrophy","volume":"224","author":"Igisu","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.braindev.2004.01.005_BIB26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1515\/bchm3.1986.367.1.241","article-title":"Occurrence of lysoganglioside lyso-GM2 (II3-Neu5Ac-gangliotriaosylsphingosine) in GM2 gangliosidosis brain","volume":"367","author":"Neuenhofer","year":"1986","journal-title":"Biol Chem Hoppe-Seyler"},{"key":"10.1016\/j.braindev.2004.01.005_BIB27","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.3101176","article-title":"Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses","volume":"235","author":"Hannun","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.braindev.2004.01.005_BIB28","first-page":"8","article-title":"Sphingosine-1-phosphate and lipid phosphatases","volume":"1582","author":"Stunff","year":"2002","journal-title":"Biochim Biochem Acta\u2014Mol Cell Biol Lipids"},{"key":"10.1016\/j.braindev.2004.01.005_BIB29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0005-2760(98)00145-3","article-title":"The role of ceramide in cell signaling","volume":"1436","author":"Perry","year":"1998","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.braindev.2004.01.005_BIB30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1442-200X.2003.01669.x","article-title":"Biochemical and molecular characterization of mutant hexosaminidase A in a Turkish family with GM2 gangliosidoses","volume":"45","author":"Sinici","year":"2003","journal-title":"Pediatr Int"},{"issue":"3","key":"10.1016\/j.braindev.2004.01.005_BIB31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1006\/mgme.1998.2742","article-title":"At least six different mutations in Hex A gene cause Tay-Sachs disease among the Turkish population","volume":"65","author":"\u00d6zkara","year":"1998","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.braindev.2004.01.005_BIB32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0387-7604(02)00213-9","article-title":"Characterization of two Turkish beta-hexosaminidase mutations causing Tay-Sachs disease","volume":"25","author":"\u00d6zkara","year":"2003","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2004.01.005_BIB33","first-page":"557","article-title":"Compound heterozygosity for metachromatic leukodystrophy and arylsulfatase A pseudodeficiency alleles is not associated with progressive neurological disease","volume":"52","author":"Penzien","year":"1993","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.braindev.2004.01.005_BIB34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000112332","article-title":"Partial enzyme deficiencies: residuel activities and the development of neurological disorders","volume":"6","author":"Conzelmann","year":"1983","journal-title":"Dev Neurosci"},{"key":"10.1016\/j.braindev.2004.01.005_BIB35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.bi.60.070191.001353","article-title":"Lysosomal storage diseases","volume":"60","author":"Neufeld","year":"1991","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.braindev.2004.01.005_BIB36","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1016\/S0021-9258(18)45628-1","article-title":"Organization of the gene encoding the human beta-hexosaminidase alpha-chain","volume":"262","author":"Proia","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2004.01.005_BIB37","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1073\/pnas.85.11.3903","article-title":"Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3\u2032 untranslated region","volume":"85","author":"Bishop","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2004.01.005_BIB38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/dna.1988.7.107","article-title":"Structural analysis of the human glucocerebrosidase genes","volume":"7","author":"Reiner","year":"1988","journal-title":"DNA"},{"key":"10.1016\/j.braindev.2004.01.005_BIB39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0378-1119(88)90511-2","article-title":"Differential expression of the human glucocerebrosidase-coding gene","volume":"73","author":"Reiner","year":"1988","journal-title":"Gene"},{"key":"10.1016\/j.braindev.2004.01.005_BIB40","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/j.1460-2075.1989.tb08382.x","article-title":"Isolation of cDNA clones encoding human acid sphingomyelinase: occurrence of alternatively processed transcripts","volume":"8","author":"Quintern","year":"1989","journal-title":"Eur Mol Biol Org J"},{"key":"10.1016\/j.braindev.2004.01.005_BIB41","doi-asserted-by":"crossref","first-page":"20655","DOI":"10.1016\/S0021-9258(19)47114-7","article-title":"Alternative splicing of beta-galactosidase mRNA generates the classic lysosomal enzyme and a beta-galactosidase related protein","volume":"264","author":"Morreau","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2004.01.005_BIB42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/dna.1990.9.119","article-title":"Isolation, characterization, and mapping of a human acid beta-galactosidase cDNA","volume":"9","author":"Yamamoto","year":"1990","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.braindev.2004.01.005_BIB43","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng1095-170","article-title":"Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism","volume":"11","author":"Sango","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.braindev.2004.01.005_BIB44","series-title":"The metabolic and molecular basis of inherited disease","first-page":"3573","article-title":"Acid ceramidase deficiency: Farber lipogranulomatosis","author":"Moser","year":"2001"},{"key":"10.1016\/j.braindev.2004.01.005_BIB45","series-title":"The metabolic and molecular basis of inherited disease","first-page":"3589","article-title":"Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies","author":"Schuchman","year":"2001"},{"key":"10.1016\/j.braindev.2004.01.005_BIB46","series-title":"The metabolic and molecular basis of inherited disease","first-page":"3635","article-title":"Gaucher disease","author":"Beutler","year":"2001"},{"key":"10.1016\/j.braindev.2004.01.005_BIB47","series-title":"The metabolic and molecular basis of inherited disease","first-page":"3669","article-title":"Galactosylceramide lipidosis: globoid cell leukodystrophy (Krabbe disease)","author":"Wenger","year":"2001"},{"key":"10.1016\/j.braindev.2004.01.005_BIB48","series-title":"The metabolic and molecular basis of inherited disease","first-page":"3695","article-title":"Metachromatic leukodystrophy","author":"Von Figura","year":"2001"},{"key":"10.1016\/j.braindev.2004.01.005_BIB49","series-title":"The metabolic and molecular basis of inherited disease","first-page":"3733","article-title":"Alpha-galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.braindev.2004.01.005_BIB50","series-title":"The metabolic and molecular basis of inherited disease","first-page":"3775","article-title":"Beta-galactosidase deficiency (beta-galactosidosis): GM1 gangliosidosis and Morquio B disease","author":"Suzuki","year":"2001"},{"key":"10.1016\/j.braindev.2004.01.005_BIB51","series-title":"The metabolic and molecular basis of inherited disease","first-page":"3827","article-title":"The GM2 gangliosidosis","author":"Gravel","year":"2001"},{"issue":"5","key":"10.1016\/j.braindev.2004.01.005_BIB52","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00003495-200262050-00002","article-title":"New prospects for the treatment of lysosomal storage diseases","volume":"62","author":"Schiffmann","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.braindev.2004.01.005_BIB53","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2990.2002.00422.x","article-title":"Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis","volume":"28","author":"Jeyakumar","year":"2002","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.braindev.2004.01.005_BIB54","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/bcmd.2000.0310","article-title":"Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease","volume":"26","author":"Altarescu","year":"2000","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.braindev.2004.01.005_BIB55","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1098\/rstb.2003.1273","article-title":"Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention","volume":"358","author":"Aerts","year":"2003","journal-title":"Philos Trans R Soc Lond B"},{"key":"10.1016\/j.braindev.2004.01.005_BIB56","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1098\/rstb.2003.1269","article-title":"Enzyme replacement therapy: conception, chaos and culmination","volume":"358","author":"Brady","year":"2003","journal-title":"Philos Trans R Soc Lond B"},{"key":"10.1016\/j.braindev.2004.01.005_BIB57","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1098\/rstb.2003.1272","article-title":"Gaucher disease and the clinical experience with substrate reduction therapy","volume":"358","author":"Zimran","year":"2003","journal-title":"Philos Trans R Soc Lond B"},{"key":"10.1016\/j.braindev.2004.01.005_BIB58","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1098\/rstb.2003.1280","article-title":"A historical perspective of the glycosphingolipids and sphingolipidoses","volume":"358","author":"Watts","year":"2003","journal-title":"Philos Trans R Soc Lond B"},{"key":"10.1016\/j.braindev.2004.01.005_BIB59","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1098\/rstb.2003.1277","volume":"358","author":"Gieselmann","year":"2003","journal-title":"Philos Trans R Soc Lond B"},{"key":"10.1016\/j.braindev.2004.01.005_BIB60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00019052-199904000-00007","volume":"12","author":"Krivit","year":"1999","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.braindev.2004.01.005_BIB61","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJM199804163381605","article-title":"Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy","volume":"338","author":"Krivit","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2004.01.005_BIB62","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.braindev.2004.01.005_BIB63","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.96.11.6388","article-title":"Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin","volume":"96","author":"Jeyakumar","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2004.01.005_BIB64","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1098\/rstb.2003.1279","article-title":"Substrate reduction therapy in mouse models of the glycosphingolipidoses","volume":"358","author":"Platt","year":"2003","journal-title":"Philos Trans R Soc Lond B"},{"key":"10.1016\/j.braindev.2004.01.005_BIB65","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood.V97.1.327","article-title":"Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation","volume":"97","author":"Jeyakumar","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.braindev.2004.01.005_BIB66","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0006-2952(99)00384-6","article-title":"N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo","volume":"59","author":"Andersson","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.braindev.2004.01.005_BIB67","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1172\/JCI9711","article-title":"Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation","volume":"105","author":"Abe","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.braindev.2004.01.005_BIB68","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2174\/1389200013338414","article-title":"Agents for the treatment of glycosphingolipid storage disorders","volume":"2","author":"Abe","year":"2001","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.braindev.2004.01.005_BIB69","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1006\/bbrc.1993.2659","article-title":"Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease","volume":"197","author":"Ishii","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.braindev.2004.01.005_BIB70","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1006\/bbrc.1995.2416","article-title":"Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease","volume":"214","author":"Okumiya","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.braindev.2004.01.005_BIB71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM200107053450104","article-title":"Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy","volume":"345","author":"Frustaci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2004.01.005_BIB72","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/cbic.200390045","article-title":"Chemical chaperones\u2014a new concept in drug research","volume":"4","author":"Kolter","year":"2003","journal-title":"ChemBioChem"},{"issue":"24","key":"10.1016\/j.braindev.2004.01.005_BIB73","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2004.01.005_BIB74","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In-vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur J Biochem"},{"issue":"1","key":"10.1016\/j.braindev.2004.01.005_BIB75","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.braindev.2004.01.005_BIB76","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1098\/rstb.2003.1270","article-title":"Future perspectives for glycolipid research in medicine","volume":"358","author":"Cox","year":"2003","journal-title":"Philos Trans R Soc Lond B"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760404000397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760404000397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T13:44:21Z","timestamp":1623764661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760404000397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":76,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S0387760404000397"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2004.01.005","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}